New hope for breast cancer survivors: drug may restore lost libido
NCT ID NCT07596212
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding the drug bupropion (Wellbutrin) to standard hormone therapy can help women with early-stage breast cancer who have lost interest in sex. About 100 women will be randomly assigned to receive either their usual hormone therapy alone or with bupropion. The goal is to see if bupropion improves sexual desire and is safe to take alongside breast cancer treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?